Loading stock data…
BCAX
$22.92+0.34 (+1.51%)
Market ClosedLast close May 11
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bicara Therapeutics Inc. in the Healthcare sector is trading at $22.92. The stock is currently near its 52-week high of $24.25, remaining 38.4% above its 200-day moving average. Technical signals show neutral RSI of 49 and bearish MACD signal, explaining why BCAX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$22.92
Potential Upside
5%
Whystock Fair Value$24.07
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$30.50+33.1%
Range$16.00 – $48.00
Fundamentals
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal g...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.50B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-34.36%
Volume
Today's trading volume
629,663
Recent News
Bicara Therapeutics Q1 Earnings Call Highlights
Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while reporting a strengthened cash position following a February public offering. On the company’s fir
Biocon's Mazumdar-Shaw sets out 5-year succession plan, names niece Claire as successor
By Rishika Sadam May 5 (Reuters) - Biocon founder and chairperson Kiran Mazumdar-Shaw plans a gradual leadership transition over the next five years, with her niece Claire Mazumdar expected to take
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000
This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider sale during active clinical development.
A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration
Earnings and shelf registration put Bicara Therapeutics (BCAX) in focus Bicara Therapeutics (BCAX) is drawing attention after reporting a fourth quarter net loss of US$37.39 million and a full year 2025 net loss of US$137.95 million, alongside a new US$70.36 million shelf registration. See our latest analysis for Bicara Therapeutics. At a share price of US$20.85, Bicara’s recent quarterly loss update and the US$70.36 million shelf registration have come alongside a 90 day share price return...
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 54.9% in Bicara Therapeutics Inc. (BCAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.